November 9, 2021

Eprontia™ (topiramate) 25mg/mL oral solution has received U.S. FDA approval to treat seizures and prevent migraines in children and adults.

  • The new approval grants three indications to Eprontia:
    • Use as a monotherapy to treat partial-onset or primary generalized tonic-clonic seizures in patients at least two years of age;
    • Use as adjunctive therapy to treat partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox Gastaut syndrome in patients at least two years old; and
    • Use as a monotherapy for preventive treatment of migraines in patients who are at least 12 years old.
  • Eprontia is the first and only FDA-approved ready-to-use liquid formulation of topiramate, its active pharmaceutical ingredient.
  • Recommended dosing is determined by multiple factors, including the patient’s age and weight,
    the condition being treated, and the clinical response to treatment.
  • Azurity Pharmaceuticals, the manufacturer, has launched Eprontia at a wholesale acquisition cost (WAC) of $665 per 473mL bottle.
January 3, 2022

FDA Expands Comirnaty Authorization to Prevent COVID-19

Read More
December 23, 2021

Merck’s COVID-19 Antiviral Granted Emergency Use Authorization

Read More
December 22, 2021

FDA Authorizes First Oral Antiviral for COVID-19

Read More
December 20, 2021

Xarelto Approved to Treat and Prevent Blood Clots in Children

Read More